サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1751189

北米の外用薬CDMOの市場規模、シェア、動向分析レポート：製品別、サービス別、最終用途別、国別、セグメント予測、2025年～2030年

North America Topical Drugs CDMO Market Size, Share & Trends Analysis Report By Product (Semi-solid, Liquid), By Service (Contract Development, Contract Manufacturing), By End Use, By Country, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 125 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.35円
北米の外用薬CDMOの市場規模、シェア、動向分析レポート：製品別、サービス別、最終用途別、国別、セグメント予測、2025年～2030年
出版日: 2025年05月23日
発行: Grand View Research
ページ情報: 英文 125 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

北米の外用薬CDMO市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、北米の外用薬CDMO市場規模は、2025年から2030年にかけて10.88%のCAGRを記録し、2030年までに272億2,000万米ドルに達すると予測されています。

研究開発活動への投資の増加と、いくつかの皮膚科疾患に対する新規治療薬へのニーズの高まりが、外用薬CDMO市場の需要拡大に寄与しています。投与が容易で副作用が最小限に抑えられることから、複数の外用液に対する消費者の嗜好が高まっていることも、市場の成長を支える要因となっています。

斬新なイノベーションと新製品開発に対するニーズの高まりが市場の需要を改善すると予想され、競争圧力と価格懸念が新薬開発と製造のアウトソーシングを企業に促しています。これが市場全体の成長を促進すると予想されます。さらに、CDMOはナノテクノロジーなどの先端技術を活用して薬剤粒子を分子レベルで操作し、薬剤の安定性とバイオアベイラビリティを高めています。さらに、マイクロカプセル化技術は繊細な成分を保護し、放出制御と標的ドラッグデリバリーを可能にすることで、治療効果を高めています。このような技術の進歩は、北米における市場成長の可能性を加速させています。

CDMOは製薬企業との協力・提携に積極的に関与しており、革新的な医薬品開発と複数の外用剤製剤の製造に関する長期契約を確保しています。例えば、2023年1月、皮膚外用剤に特化した著名なプロバイダーであるスイス系米国CDMOは、EveryDropディスペンシング・プラットフォームの発明者であるLiquiGlideと提携しました。この提携により、同社はLiquiGlideの革新的な無毒性の滑りやすい表面技術を利用し、液体と固体間の摩擦をなくし、消費者向けパッケージ商品の製品廃棄物をなくします。

北米の外用薬CDMO市場レポートハイライト：

  • 製品タイプ別では、半固形製剤部門が2024年の売上高シェア66.47%以上で市場を独占しています。これは、投与が容易であることや、副作用がいくつかあるため経口投与よりも外用薬の方が患者に好まれることなど、多くの利点があるためであり、これが同部門の需要を促進すると予想されます。
  • サービスタイプ別では、受託製造部門が予測期間中に大幅なCAGRで成長する見込みです。
  • スポンサー別では、製薬会社が2024年に最大の市場シェアを占めています。革新的な外用薬を開発・商品化するための製薬企業による研究開発投資の開拓が、市場収益の成長を後押しすると予想されます。
  • 米国は北米の外用薬CDMO業界を支配しているが、これは同地域における市場参入企業の存在感の強さ、質の高いヘルスケアに対する政府の支援、化粧品に対する需要の高さといった要因によるものです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 北米の外用薬CDMO市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
  • 価格分析
  • 外用薬CDMO生産能力の見通し
    • CDMO製造コンテナ容量
    • 外用薬容器容量（製品タイプ）
  • 北米外用薬CDMO市場展望（製品カテゴリー別）
    • 北米の外用薬CDMO市場シェア（製品カテゴリー別、2024年、％）
    • 処方薬
    • ジェネリック医薬品
    • 市販薬（OTC薬）
  • 北米外用薬CDMO市場分析ツール
    • ポーターのファイブフォース分析
    • PESTEL分析
    • COVID-19の影響分析
    • 米国関税の影響分析

第4章 北米の外用薬CDMO市場：製品推定・動向分析

  • 製品市場シェア、2024年と2030年
  • セグメントダッシュボード
  • 北米の外用薬CDMO市場：製品別展望
  • 2018年から2030年までの市場規模と予測および動向分析
    • 半固形製剤
    • 液体製剤
    • 固形製剤
    • 経皮吸収型製品

第5章 北米の外用薬CDMO市場：サービス推定・動向分析

  • サービス市場シェア、2024年と2030年
  • セグメントダッシュボード
  • 北米の外用薬CDMO市場：サービス展望
  • 2018年から2030年までの市場規模と予測および動向分析
    • 受託開発
    • 受託製造

第6章 北米の外用薬CDMO市場：最終用途の推定・動向分析

  • 最終用途市場シェア、2024年および2030年
  • セグメントダッシュボード
  • 北米の外用薬CDMO市場：最終用途別展望
  • 2018年から2030年までの市場規模と予測および動向分析
    • 製薬会社
    • バイオ医薬品企業
    • その他

第7章 北米の外用薬CDMO市場：国別推定・動向分析

  • 国別市場シェア分析、2024年および2030年
  • 国別市場ダッシュボード
  • 国別市場スナップショット
  • 市場規模、予測、動向分析、2018～2030年
  • 米国
    • 主要国の動向
    • 競合シナリオ
    • 規制の枠組み
  • カナダ
    • 主要国の動向
    • 競合シナリオ
    • 規制の枠組み
  • メキシコ
    • 主要国の動向
    • 競合シナリオ
    • 規制の枠組み

第8章 競合情勢

  • 企業/競合の分類
    • マーケットリーダー
    • 新興プレーヤー
  • 企業市場シェア/評価分析、2024年
  • 企業プロファイル
    • The Lubrizol Corporation
    • Cambrex Corporation
    • Contract Pharmaceuticals Limited
    • Bora Pharmaceutical CDMO
    • Ascendia Pharmaceuticals
    • Pierre Fabre SA
    • Piramal Pharma Solutions
    • DPT Laboratories, LTD.
    • MedPharm Ltd.
    • Zenvisionpharma
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global topical drugs CDMO: market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Table 4 Global topical drugs: market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Table 5 Development stages baseline model parameter estimates, By topical drugs
  • Table 6 Global topical drugs CDMO manufacturing container capacity/batch
  • Table 7 Global topical drugs capacity, by product type (per unit)
  • Table 8 Global topical drugs capacity, by container type (per unit)
  • Table 9 North America topical drugs CDMO market share, by product category, 2024 (%)
  • Table 10 List of major prescription drugs, by product type (2024)
  • Table 11 List of major generic drugs, by product type (2024)
  • Table 12 List of major OTC drugs, by product type (2024)
  • Table 13 North America topical drugs CDMO market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 14 North America topical drugs CDMO market estimates and forecasts, by semi-solid formulations, 2018 - 2030 (USD Million)
  • Table 15 North America topical drugs CDMO market estimates and forecasts, by liquid formulation drugs, 2018 - 2030 (USD Million)
  • Table 16 North America topical drugs CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 17 North America topical drugs CDMO market estimates and forecasts, by contract development, 2018 - 2030 (USD Million)
  • Table 18 North America topical drugs CDMO market estimates and forecasts, by contract manufacturing, 2018 - 2030 (USD Million)
  • Table 19 North America topical drugs CDMO market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 20 North America topical drugs CDMO market estimates and forecasts, by country, 2018 - 2030 (USD Million)
  • Table 21 U.S. topical drugs CDMO market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 22 U.S. topical drugs CDMO market estimates and forecasts, by semi-solid formulations, 2018 - 2030 (USD Million)
  • Table 23 U.S. topical drugs CDMO market estimates and forecasts, by liquid formulation drugs, 2018 - 2030 (USD Million)
  • Table 24 U.S. topical drugs CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 25 U.S. topical drugs CDMO market estimates and forecasts, by contract development, 2018 - 2030 (USD Million)
  • Table 26 U.S. topical drugs CDMO market estimates and forecasts, by contract manufacturing, 2018 - 2030 (USD Million)
  • Table 27 U.S. topical drugs CDMO market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 28 Canada topical drugs CDMO market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 29 Canada topical drugs CDMO market estimates and forecasts, by semi-solid formulations, 2018 - 2030 (USD Million)
  • Table 30 Canada topical drugs CDMO market estimates and forecasts, by liquid formulation drugs, 2018 - 2030 (USD Million)
  • Table 31 Canada topical drugs CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 32 Canada topical drugs CDMO market estimates and forecasts, by contract development, 2018 - 2030 (USD Million)
  • Table 33 Canada topical drugs CDMO market estimates and forecasts, by contract manufacturing, 2018 - 2030 (USD Million)
  • Table 34 Canada topical drugs CDMO market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 35 Mexico topical drugs CDMO market estimates and forecasts, by product, 2018 - 2030 (USD Million)
  • Table 36 Mexico topical drugs CDMO market estimates and forecasts, by semi-solid formulations, 2018 - 2030 (USD Million)
  • Table 37 Mexico topical drugs CDMO market estimates and forecasts, by liquid formulation drugs, 2018 - 2030 (USD Million)
  • Table 38 Mexico topical drugs CDMO market estimates and forecasts, by service, 2018 - 2030 (USD Million)
  • Table 39 Mexico topical drugs CDMO market estimates and forecasts, by contract development, 2018 - 2030 (USD Million)
  • Table 40 Mexico topical drugs CDMO market estimates and forecasts, by contract manufacturing, 2018 - 2030 (USD Million)
  • Table 41 Mexico topical drugs CDMO market estimates and forecasts, by end use, 2018 - 2030 (USD Million)
  • Table 42 Company profiles: Company overview
  • Table 43 Company profiles: Financial performance
  • Table 44 Company profiles: Service benchmarking
  • Table 45 Key company initiating service launches/upgrades
  • Table 46 Key companies initiating mergers/acquisitions/joint ventures
  • Table 47 Key companies initiating partnerships
  • Table 48 Key companies initiating expansion
  • Table 49 Key companies initiating others

List of Figures

  • Fig. 1 North America topical drugs CDMO market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Commodity flow analysis
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Global topical drugs CDMO market outlook, 2023 (USD Billion)
  • Fig. 13 Global topical drugs market outlook, 2023 (USD Billion)
  • Fig. 14 North America topical drugs CDMO market dynamics
  • Fig. 15 Porter's Five Forces analysis
  • Fig. 16 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 17 North America Topical Drugs CDMO market: Product Type outlook and key takeaways
  • Fig. 18 North America Topical Drugs CDMO market: Product Type movement analysis
  • Fig. 19 Semi-solid formulations market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Creams market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Ointments market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Lotions market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Liquid formulations market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Suspensions market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Solutions market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Solid formulations market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Transdermal products market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 North America Topical Drugs CDMO market: Service type outlook and key takeaways
  • Fig. 30 North America Topical Drugs CDMO market: Service type movement analysis
  • Fig. 31 Contract development market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Formulation development market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 33 Analytical testing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Stability testing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Contract manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Commercial market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 North America Topical Drugs CDMO market: sponsors outlook and key takeaways
  • Fig. 40 North America Topical Drugs CDMO market: sponsors movement analysis
  • Fig. 41 Pharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Biopharmaceutical companies market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 North America Topical Drugs CDMO market revenue, by country, 2023 & 2030 (USD Million)
  • Fig. 45 Regional outlook, 2023 & 2030
  • Fig. 46 Regional Market Share Analysis, 2023 & 2030
  • Fig. 47 North America Topical Drugs CDMO market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 48 Key country dynamics
  • Fig. 49 U.S. Topical Drugs CDMO market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 50 Key country dynamics
  • Fig. 51 Canada Topical Drugs CDMO market estimates and forecasts, 2018 - 2030 (USD million)
  • Fig. 52 Market participant categorization
  • Fig. 53 Market participant categorization
  • Fig. 54 Heat map analysis
目次
Product Code: GVR-4-68040-188-4

North America Topical Drugs CDMO Market Growth & Trends:

The North America topical drugs CDMO market size is anticipated to reach USD 27.22 billion by 2030, registering a CAGR of 10.88% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing investment in R&D activities coupled with rising need for novel therapeutics for several dermatological conditions contributes to the growing demand for topical drugs CDMO market. Rising consumer preference for several topical solutions owing to ease of administration and minimized side effects are other factors supporting the growth of the market.

The growing need for novel innovation and new product developments are expected to improve the demand in the market, and competitive pressure & pricing concerns are driving companies to outsource new drug development & manufacturing. This is expected to drive overall market growth. Moreover, CDMOs are leveraging several advanced technologies such as nanotechnology to manipulate drug particles at the molecular level, enhancing drug stability and bioavailability. Moreover, microencapsulation techniques protect sensitive ingredients, allowing for controlled release and targeted drug delivery, amplifying therapeutic outcomes. Such technological advancements are accelerating market growth potential in North America.

CDMOs are actively involved in collaboration & partnerships with pharmaceutical companies to secure long-term contracts for innovative drug development and manufacturing of several topical formulations, which is expected to spur market demand. For instance, in January 2023, Swiss-American CDMO, a prominent provider specializing in topical skin care products, collaborated with LiquiGlide, the inventor of the EveryDrop dispensing platform. Through this collaboration, the company will utilize LiquiGlide's innovative nontoxic slippery surface technology to eliminate friction between liquids & solids and product waste for consumer-packaged goods.

North America Topical Drugs CDMO Market Report Highlights:

  • Based on product type, the semi-solid formulations segment dominated the market with a revenue share of more than 66.47% share in 2024, owing to numerous advantages including ease of administration and patient preference for topical drugs compared to the oral route of administration owing to several adverse effects, which is expected to drive segment demand
  • Based on service type, the contract manufacturing segment is expected to grow at the substantial CAGR over the forecast period
  • Based on sponsors, the pharmaceutical companies segment held the largest market share in 2024. Growing R&D investments by several pharmaceutical companies to develop and commercialize innovative topical drugs is anticipated to boost market revenue growth
  • The U.S. dominated the North America topical drugs CDMO industry owing to factors such as strong presence of market participants in the region, government support for quality healthcare and high demand for cosmetic products

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Parent Market Analysis (Model 2)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. North America Topical Drugs CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Technological advancements & growing R&D investments
      • 3.2.1.2. Rising demand for topical medications
      • 3.2.1.3. Expansion of manufacturing capacities and partnerships
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Compliance with strict regulatory requirements
      • 3.2.2.2. Limited efficacy in certain conditions limits the adoption of topical products
  • 3.3. Pricing Analysis
  • 3.4. Topical Drugs CDMO Capacity Outlook
    • 3.4.1. CDMO Manufacturing Container Capacity
    • 3.4.2. Topical Drugs Container Capacity By Product Type
  • 3.5. North America Topical Drugs CDMO Market Outlook By Product Category
    • 3.5.1. North America Topical Drugs CDMO Market Share, By Product Category, 2024 (%)
    • 3.5.2. Prescription Drugs
      • 3.5.2.1. Segment Overview
      • 3.5.2.2. Major Prescription Drugs, By Product Type
    • 3.5.3. Generic Drugs
      • 3.5.3.1. Segment Overview
      • 3.5.3.2. Major Generic Drugs, By Product Type
    • 3.5.4. Over-the-counter (OTC) Drugs
      • 3.5.4.1. Segment Overview
      • 3.5.4.2. Major OTC Drugs, By Product Type
  • 3.6. North America Topical Drugs CDMO Market Analysis Tools
    • 3.6.1. Porter's Five Forces Analysis
    • 3.6.2. PESTEL Analysis
    • 3.6.3. COVID-19 Impact Analysis
    • 3.6.4. U.S. Tariff Impact Analysis

Chapter 4. North America Topical Drugs CDMO Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. North America Topical Drugs CDMO Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Semi-solid Formulations
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.2. Creams
        • 4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.3. Ointments
        • 4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.4. Lotions
        • 4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.1.5. Others
        • 4.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Liquid Formulations
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.2. Suspensions
        • 4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.3. Solutions
        • 4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Solid Formulations
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Transdermal Products
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. North America Topical Drugs CDMO Market: Service Estimates & Trend Analysis

  • 5.1. Service Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. North America Topical Drugs CDMO Market by Service Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Contract Development
      • 5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.2. Formulation Development
        • 5.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.3. Analytical Testing
        • 5.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.4. Stability Testing
        • 5.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.1.5. Others
        • 5.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Contract Manufacturing
      • 5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.2. Clinical
        • 5.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 5.4.2.3. Commercial
        • 5.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. North America Topical Drugs CDMO Market: End Use Estimates & Trend Analysis

  • 6.1. End Use Market Share, 2024 & 2030
  • 6.2. Segment Dashboard
  • 6.3. North America Topical Drugs CDMO Market by End Use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Pharmaceutical Companies
      • 6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.2. Biopharmaceutical Companies
      • 6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Others
      • 6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. North America Topical Drugs CDMO Market: Country Estimates & Trend Analysis

  • 7.1. Country Market Share Analysis, 2024 & 2030
  • 7.2. Country Market Dashboard
  • 7.3. Country Market Snapshot
  • 7.4. Market Size, & Forecasts, Trend Analysis, 2018 to 2030
  • 7.5. U.S.
    • 7.5.1. Key country dynamics
    • 7.5.2. Competitive scenario
    • 7.5.3. Regulatory framework
    • 7.5.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Canada
    • 7.6.1. Key country dynamics
    • 7.6.2. Competitive scenario
    • 7.6.3. Regulatory framework
    • 7.6.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Mexico
    • 7.7.1. Key country dynamics
    • 7.7.2. Competitive scenario
    • 7.7.3. Regulatory framework
    • 7.7.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
    • 8.1.1. Market Leaders
    • 8.1.2. Emerging Players
  • 8.2. Company Market Share/Assessment Analysis, 2024
  • 8.3. Company Profiles
    • 8.3.1. The Lubrizol Corporation
      • 8.3.1.1. Company overview
      • 8.3.1.2. Financial performance
      • 8.3.1.3. Product/service benchmarking
      • 8.3.1.4. Strategic initiatives
    • 8.3.2. Cambrex Corporation
      • 8.3.2.1. Company overview
      • 8.3.2.2. Financial performance
      • 8.3.2.3. Product/service benchmarking
      • 8.3.2.4. Strategic initiatives
    • 8.3.3. Contract Pharmaceuticals Limited
      • 8.3.3.1. Company overview
      • 8.3.3.2. Financial performance
      • 8.3.3.3. Product/service benchmarking
      • 8.3.3.4. Strategic initiatives
    • 8.3.4. Bora Pharmaceutical CDMO
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product/service benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Ascendia Pharmaceuticals
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product/service benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Pierre Fabre S.A.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product/service benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Piramal Pharma Solutions
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product/service benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. DPT Laboratories, LTD.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product/service benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. MedPharm Ltd.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product/service benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Zenvisionpharma
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product/service benchmarking
      • 8.3.10.4. Strategic initiatives